INTRODUCTION
The burden of cancer is steadily increasing in the HIV population. In the years before widespread availability of antiretroviral therapy (ART), the most common cancers in the HIV population were Kaposi sarcoma and non-Hodgkin lymphoma [1] [2] [3] [4] [5] [6] . These cancers, along with cervical cancer, were characterized as AIDS-defining malignancies [7] . The epidemiology of cancer in the HIV population has changed markedly during the two decades since the introduction of effective ART in the United States, in large part because of aging of the HIV population [8] . Non-AIDS-defining malignancies (NADMs) associated with advanced age and lifestyle, such as lung and anal cancer, have become more common [1, 9] .
Although the rising burden of NADM-associated mortality in the HIV population is well documented [10] , we are currently not adequately treating cancer in this population. In recent years, several population-based studies have highlighted a major healthcare disparity: HIV-infected cancer patients in the United States are less likely to receive cancer treatment compared with their uninfected counterparts [11, [12] [13] && ]. In this review, we summarize the available literature related to this cancer treatment disparity, highlight the impact of the disparity on cancer survival, discuss possible reasons for the disparity and suggest new avenues of research into this increasingly important public health topic.
'HIV' to identify reports: 'cancer', 'cancer treatment', 'treatment disparity', 'cancer survival' and 'cancer patient outcome'. We examined the results of all articles; nine reported cancer treatment rates according to HIV status in the United States, of which only two were published in the last 12-18 months. Given the paucity of literature on cancer treatment rates in the United States HIV population, the five articles published since 2013 from population-based data sources were included in this review.
Current treatment paradigms in HIV-associated cancer
For a few HIV-associated malignancies, such as non-Hodgkin lymphoma and anal cancer, there are high-quality studies with specific guidance on how to treat HIV-infected patients [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, for many other cancer types, particularly NADMs, lack of high-quality, prospective studies [23] has led to a paucity of clinical guidelines for treating HIV-infected patients. Several studies are ongoing or in development, which will provide more information about how best to treat HIVinfected cancer patients. Until then, cancer patients with well controlled HIV infection should be treated similarly to uninfected patients, as suggested by the currently available literature [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
Survival of HIV-infected cancer patients
The survival of HIV-infected patients has drastically changed since the start of the epidemic [8, 38] . In contrast with the pre-ART era, HIV-infected people now have a life expectancy approaching that of the general population [39] . Nonetheless, in studies of HIV-infected cancer patients, differences in overall survival compared with uninfected cancer patients have been noted [40, 41] . These differences may be partly attributable to death from AIDS-related complications.
However, recent studies evaluating cancer outcomes have demonstrated higher cancer-specific mortality in HIV-infected people compared with the general population for several cancer types [42] [43] [44] . Among other factors, differences in cancer treatment may contribute to decreased survival.
Cancer treatment disparities in the United States
One of the first studies to demonstrate a cancer treatment disparity according to patient HIV status utilized data from the HIV-AIDS Cancer Match Study (HACM) to examine lung cancer patients diagnosed in Texas [11] . The study found that HIV-infected lung cancer patients were markedly less likely to receive cancer treatment compared with uninfected patients [adjusted odds ratio (aOR) 0.39, 95% confidence interval (CI) 0.30-0.52]. Among patients with early stage nonsmall cell lung cancer (NSCLC), standard-of-care therapies aimed at cure were also significantly less likely to be offered to HIV-infected patients (aOR 0.35, 95% CI 0.17-0.71). Notably, patients with AIDS had lower overall and cancer-specific survival compared with uninfected patients in this study (cancer-specific multivariate hazard ratio 1.38 95% CI 1.16-1.65), and lack of cancer treatment may have contributed to that survival deficit.
However, two other studies of HIV-infected lung cancer patients using the SEER-Medicare claims database did not show an association between HIV status and cancer treatment [43, 45] . Approximately 60% of lung cancer patients received guidelineconcordant care, regardless of HIV status, and a similar proportion of stages I-IIIa NSCLC patients received stage-appropriate therapy. The lack of a treatment disparity by HIV status observed in these studies may be related to a few notable differences between the SEER-Medicare and HACM data sets. First, all patients in the SEER-Medicare studies had health insurance, which could have disproportionately raised the treatment rates for HIV-infected lung cancer patients. Second, nearly all Medicare patients are 65 years or older, thereby sampling an older HIV-infected cancer population. Cancer treatments rates are generally lower in the elderly population [46, 47] , possibly obscuring differences by HIV status. Indeed, the observed treatment rate for lung cancer patients in these studies was lower than that reported in studies using other national data sets (65-70% for HIV infected and 75-85% for HIV uninfected) [11, [12] [13] && ].
KEY POINTS
The burden of cancer is large and growing in the HIV population, and cancer is the leading cause of non-AIDS death in the HIV population.
HIV-infected patients are less likely to receive cancer treatment compared with uninfected cancer patients for many common cancers, even after factoring in differences in race, cancer stage, insurance status and noncancer general health.
Appropriate cancer treatment can extend quantity and quality of life, and additional research dedicated to elucidating the underlying reasons for the cancer treatment disparity is urgently needed to improve cancer care and outcomes in the HIV population.
Another, larger study using HACM data looked at several common cancer types in Connecticut, Michigan and Texas [12 & ]. Once again, using a conservative definition of cancer treatment that included any cancer therapies (even if not considered standard therapy), HIV-infected cancer patients were less likely to receive cancer treatment compared with uninfected cancer patients for several cancer types (modeled as lack of cancer treatment; aOR ranging from 1.39 for diffuse large B-cell lymphoma to 1.89 for colorectal cancer). For a subset of early stage cancers wherein cure is possible with appropriate treatment, HIV-infected people remained significantly less likely to receive treatment (diffuse large B-cell lymphoma aOR 2.02 95% CI 1.50-2.72; NSCLC aOR 2.43 95% CI 1.46-4.03; colon cancer aOR 4.77 95% CI 1.76-12.96).
One important limitation of these studies is that data from HACM did not include information on insurance status and medical comorbidities, both of which are important contributors to receipt of appropriate cancer treatment. HIV-infected people in the United States are more likely to be uninsured or underinsured [48, 49] , and also more likely to have medical comorbidities [50] . Studies have demonstrated that in the general cancer population, those with no insurance or Medicaid are less likely to receive cancer treatment [51] . Similarly, medical comorbidities may affect candidacy for cancer treatment [52] . Therefore, the differences observed in the population-based studies could be explained in part by differences in insurance status and overall noncancer health in the HIV cancer population.
To address this limitation, a study was conducted using the National Cancer Database, a hospital-based registry representing approximately 70% of incident cancer cases diagnosed in the United States [13 && ] In this study, 10,265 HIVinfected patients and 2,219,232 HIV-uninfected patients under the age of 65 with several common cancer types were examined. HIV-infected patients were more likely to be uninsured or underinsured (35% private insurance among HIV-infected group vs. 73% in HIV-uninfected group, P < 0.001), and were more likely to have medical comorbidities (7.4% HIV-infected Charlson score 2þ vs. 4% HIVuninfected Charlson score 2þ, P < 0.001). However, even after factoring in differences in insurance and medical comorbidities, HIV-infected cancer patients were significantly more likely to be untreated for all cancer types (aOR range 1.48-2.81), except for anal cancer (aOR 1.20, 95% CI 0.83-1.71).
The presented data provide a sobering reality of subpar cancer care provided to the United States HIV population. However, the differences in cancer treatment could be even greater than that observed. The studies presented often included any cancer treatment delivered, not the standard-of-care therapy, and therefore the treatment disparity may be even greater when examining only standard cancer treatments. The studies also did not ascertain the specific cancer regimens received. For example, the HIV-infected patients who were treated may have received lower doses or fewer cycles of chemotherapy and/or radiation. Patients may have started, but not completed cancer therapy and early discontinuation is generally not captured in registry data. These types of differences by HIV status have not yet been demonstrated, although if present, they could meaningfully affect cancer outcomes.
Reasons for the observed cancer treatment disparity
It remains unclear why HIV-infected patients are less likely to receive cancer treatment than uninfected patients. In cancer registry studies, sociodemographic and clinical factors associated with lack of cancer treatment in the HIV-infected patients include older age, black or Hispanic race/ethnicity, lack of private insurance, intravenous drug use, low CD4 cell count and distant or unknown cancer stage [12 & ,13
&&
,53]. In addition to these factors, there are likely various patient-driven, provider-driven and health systems-related issues that contribute. It is possible that HIV-infected patients are offered cancer therapy at rates similar to uninfected patients, but more often decline treatment. One potential explanation is that patients may feel overwhelmed by the dual burden of disease, particularly for two diseases that may require lifelong therapy. Other sociodemographic factors that are not measured in cancer registries, such as insufficient finances for copays or lack of transportation, may hinder initiation or completion of cancer therapy. However, no literature has been published addressing specific patient barriers to appropriate cancer care in this setting.
Physicians may choose to withhold treatment from HIV-infected cancer patients because of lack of knowledge about appropriate treatment paradigms. Historically, patients with HIV were excluded from cancer clinical trials by virtue of their HIV infection. More recently, the National Cancer Institute Cancer Therapy Evaluation Program has recommended that patients with well controlled HIV no longer be excluded because of their HIV status [23] . The lack of randomized clinical trial data has led to lack of management guidelines specific to HIVinfected patients, which may also decrease provider comfort with cancer treatment in the setting of HIV. Oncologists may be concerned about greater than expected side-effects from cancer treatment, interactions between cancer drugs and HIV drugs and the effectiveness of cancer treatment in the HIV population. For anal cancer, both high-quality randomized clinical trial data and management guidelines specific to HIV exist [54] , and, no difference in cancer treatment rates was observed in the studies presented. Interestingly, similarly high-quality studies and guidelines exist for management of non-Hodgkin lymphoma in HIVinfected patients [55] , but differences in treatment rates were observed in these studies.
A recent survey study of United States medical and radiation oncologists aimed to identify provider practice patterns for HIV-infected cancer patients [56] . The primary outcome was self-reported delivery of standard cancer therapy to patients with well-controlled HIV infection based on responses to specialty-specific case scenarios. Of the 276 respondents (60% response rate), less than 80% of providers said they would offer standard cancer therapy to HIV-infected patients. Furthermore, 70% indicated that insufficient guidelines were available to aid in clinical decision-making and 45% said that they rarely or never discussed the cancer management plan with the patient's HIV specialist. Physicians who were more comfortable discussing cancer prognosis and treatment side-effects were more likely to offer standard cancer treatment (aOR 1.52 95% CI 1.12-2.07), whereas physicians who believed that HIV-infected patients were more likely to have treatment toxicity or decreased efficacy of therapy were less likely to offer standard cancer therapy (aOR 0.67 95% CI 0.53-0.85). This study suggests that provider education on appropriate cancer treatment for HIV-infected patients may increase treatment rates. In addition, greater interdisciplinary collaboration is needed to safely deliver treatment and ensure the best outcome from both HIV and cancer.
Health systems-related factors also likely contribute to differences in cancer treatment rates. Unfortunately, in the United States, race and health insurance status affect access to cancer treatment. Studies examining the impact of race in the general cancer population show that black and Hispanic patients are more likely to present with advanced cancer stage and less likely to receive cancer treatment [57] . A recent study showed a similar finding for patients with no insurance or Medicaid -they are less likely to receive cancer treatment [51] . The United States HIV population has a high proportion of black and Hispanic individuals, as well as high rates of no insurance or Medicaid insurance [58] . Although the cancer treatment disparity was still observed even after controlling for race and insurance status, this is a major public health issue that needs to be addressed. Policy changes are needed to ensure that cancer treatment is available for all patients, regardless of HIV status.
Scope of the impact of cancer treatment disparities
Stage-appropriate cancer treatment can be lifesaving. Even for advanced stage cancer, palliative treatment can improve survival [59] . Withholding treatment from HIV-infected patients can lead to lower life expectancy as well as symptoms from untreated cancer and lower quality of life. Loss of quantity and quality of life may have tremendous psychological, social and economic impact on HIV-infected patients and their families in terms of mental health, family planning, lost wages and diminished productivity. Furthermore, equal access to standard cancer treatment, as well as novel therapies available only through clinical trials, is an issue of equity. All patients, regardless of HIV status, should have equal access to the best available cancer therapies.
Further research needs
The magnitude of the cancer treatment disparity in HIV-infected cancer patients is alarming. Thus far, most of the research in this area has focused on identifying and quantifying the extent of the problem. Additional research is urgently needed to determine the underlying drivers so that interventions can be designed to mitigate these factors. Studies designed to understand and address the cancer treatment disparity should be prioritized in order to improve unequal patient outcomes from cancer in the HIV population.
In addition, research aimed at studying cancer treatment toxicity and efficacy in the HIV population should also be prioritized. Although the best available evidence we currently have suggests that patients with well-controlled HIV infection should be treated similarly to uninfected patients, the data varies in extent and quality, and by cancer type. Several novel randomized clinical trials are underway, particularly in organizations such as the AIDS Malignancy Consortium. Management paradigms are being developed and tested in global settings with high HIV burden. Appropriate dissemination of these clinical trial results will be a critical step in improving cancer care delivery.
CONCLUSION
Cancer treatment disparities are large and significant in the HIV-infected population in the United States, and the factors driving the disparities are not understood. This means that HIV-infected cancer patients are receiving suboptimal cancer treatment. With modern ART, people with HIV are living longer and therefore developing cancer more often. Cancer is the leading cause of non-AIDS death in HIV-infected patients. Given the rapidly growing burden of cancer and the high observed cancer mortality, urgent attention and research resources are needed to understand and remedy the treatment disparity. Without drastic changes to improve cancer treatment in the HIV population, we stand to lose many to potentially curable cancers. HIV specialists, oncologists, patients and health policy makers need to be aware of the current disparity in care and collaborate in research, clinical initiatives and policy-making to improve cancer treatment and outcomes for HIV-infected cancer patients.
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